Lavipharm S.A (LAVI) Fair Value & Analysis
Healthcare · GR · Market cap €266M
Fair value as of: Jun 24, 2026
Analysis
Lavipharm S.A (LAVI) currently trades at €1.61, while our model-based Fair Value estimate is €0.5600 — implying the stock looks roughly 65.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; and over the counter (OTC) drugs, such as antiseptics, anagelsics, and anti-lice treatment products. It also provides a range of skincare products focused on health. The company was founded in 1911 and is based in Paiania, Greece.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Lavipharm S.A (LAVI) undervalued?
What is the fair value of LAVI?
What is the quality score of LAVI?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.